Patients who start long-term buprenorphine treatment are less likely to use opioids

In a first-ever randomized trial, patients at a short-term inpatient program began long-term outpatient treatment with buprenorphine before discharge, with better outcomes than detox patients.

Three out of four people who complete an inpatient opioid withdrawal management program--commonly known as "detox"--relapse within a month, leading to a "revolving door" effect. Few successfully transition from the inpatient setting to long-term treatment with proven medications such as buprenorphine, methadone, or naltrexone to prevent overdose.

But patients who start long-term buprenorphine treatment at a detox program, instead of going through detox and getting a referral for such treatment at discharge, are less likely to use opioids illicitly over the following six months, and more likely to keep up treatment, according to a first-of-its-kind study led by a Boston University School of Public Health (BUSPH) researcher and published in the journal Addiction.

The idea of detox--getting inpatient treatment for a few days and expecting to quit opioids--has always been magical thinking. We've quantified here for the first time how successful we can be if we use short-term inpatient programs as starting grounds for long-term treatment."

Dr. Michael Stein, Study Lead Author, Professor and Chair of health law, policy & management, BUSPH

In the randomized trial, 59 patients at the Stanley Street Treatment and Resources program (SSTAR) in Fall River, Mass., went through a standard buprenorphine-assisted detox program (including then tapering off buprenorphine). Another 56 patients received the typical first-day buprenorphine treatment, then went on to a daily dose of buprenorphine, and were discharged as already-established patients at SSTAR's nearby primary healthcare center, with an outpatient appointment for the following week and a prescription to be able to continue taking their daily dose of buprenorphine until then.

The researchers found that these participants were more likely to be taking buprenorphine up to six months after discharge than the patients who had gone through standard detox. They were also less likely to use illicit opioids, "thereby lowering the overdose risk that comes from use of fentanyl and other lethal opioids," Stein says.

Journal reference:

Stein, M. et al. (2019) Initiating buprenorphine treatment for opioid use disorder during short‐term in‐patient ‘detoxification’: a randomized clinical trial. Addiction.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study explores loneliness among men in the COVID-19 pandemic